InflaRx N.V. is a clinical-stage biopharmaceutical company. It focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. InflaRx N.V. is based in Germany.
| Revenue (Most Recent Fiscal Year) | $0.18M |
| Net Income (Most Recent Fiscal Year) | $-49.85M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 308.49 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.77 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -33646.85% |
| Net Margin (Trailing 12 Months) | -33362.70% |
| Return on Equity (Trailing 12 Months) | -64.17% |
| Return on Assets (Trailing 12 Months) | -53.39% |
| Current Ratio (Most Recent Fiscal Quarter) | 5.28 |
| Quick Ratio (Most Recent Fiscal Quarter) | 4.86 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 0.38 |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.11 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.14 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.85 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.82 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 67.13M |
| Free Float | 56.19M |
| Market Capitalization | $57.07M |
| Average Volume (Last 20 Days) | 0.72M |
| Beta (Past 60 Months) | 1.57 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 16.30% |
| Percentage Held By Institutions (Latest 13F Reports) | 42.39% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |